BioMimetic share purchases by Novo A/S

Franklin-based BioMimetic Therapeutics (NASDAQ: BMTI) and Novo A/S today announced Novo A/S has "implemented a 10b5-1 trading plan, providing for open market purchases of BioMimetic common stock... Currently, Novo A/S beneficially owns approximately 17% of the common stock of BioMimetic. Thorkil Christensen, CFO of Novo A/S and a member of BioMimetic’s board of directors, noted that, "Novo does not intend to increase its ownership in BioMimetic in excess of 25%, nor does it intend to seek to acquire or exercise control over the company. Novo intends to purchase additional securities pursuant to the announced program for investment purposes."